to evaluate the leptin (LE) serum concentration and the sympathetic activity by the serum concentration of adrenaline (A) and noradrenaline (NA) in patients with OSAS before and after 8 months of therapy with nCPAP.
The study group was consisted of 40 men with OSAS (mean age 50.6±10.0 yrs, range 30-71) with the following antropometrical parameters: mean body mass 97.8 ± 23.8kg, mean height 175.7± 8.3cm, BMI 31.5±6.3kg/m2, WHR 0.99±0.07. 14 patients were overweight, 23 were obese. Arterial hypertension was diagnosed in 7 cases, 3 patients were treated due to ischaemic heart disease. The control group was consisted of 12 men without OSAS. Methods: the diagnosis of OSAS (AHI > 10) was confirmed by polisomnography. Blood samples were taken after overnight fasting. The serum concentration of LE by RIA method, A and NA by HPLC were evaluated and basic biochemical investigations were performed.
After 8 months 33 patients underwent control blood investigations, among them 20 subjects were treated with nCPAP. At the begining of the study the midlle serum concentrationof A, NA and LE were 64,0±30,4 pg/mL : 517,0 ±158,0 pg/mL : 16,2± 12,8 ng/mL in the study group. Results of A, NA, LE before and after 8 months of 20 treated by CPAP patients were 55,7±20,4 pg/mL: 521,4±142,8pg/mL : 14,6±4,2 ng/mL vs 52,66±26,52pg/mL:472,48±160,97pg/mL:12,31±3,87ng/mL. The concentration of A, NA and LE in control group were 46,0±28,2pg/mL: 430,8±106,5 pg/mL :11,38±6,93 ng/ml.
In patients with OSAS comparing to the control group an increased sympathetic activity and higher leptin concentration were observed. There were tendency to decrease of sympathetic activity and leptin concentration, but there was not significant.
The nCPAP therapy seems to have influence on sympathetic activity and leptin concentration in patients with OSAS. This kind of therapy could have ability to lower the risk of cardiovascular diseases in patients with OSAS.
R. Chazan, None.